Company Overview
Guardant Health, Inc. operates as a precision oncology company that provides blood and tissue tests, along with comprehensive data sets, to support diagnostic and research efforts both in the United States and internationally. The company's core offerings include the Guardant360 CDx test, which functions as a liquid biopsy for tumor mutation profiling, and the Guardant360 Liquid test, which measures over 740 genes to support clinical applications. This entity functions within the broader Healthcare sector, specifically focusing on the Diagnostics & Research industry, positioning it as a specialized player in medical technology and genomic analysis. The company demonstrates significant scale with a market capitalization of $11.68B and annual revenue of $982.02M, supported by an employee base of 2490 individuals. These financial figures indicate that Guardant Health commands a substantial valuation relative to its current sales volume, reflecting investor confidence in its technological capabilities despite the company currently operating at a loss.
Financial Health
The company reported a trailing twelve-month revenue of $982.02M, while simultaneously posting a net income loss of $-416,276,992 and an EBITDA of $-396,561,984. The substantial gap between the positive revenue figure and the significant negative net income reveals a heavy cost structure where operating expenses, likely driven by research and development and commercialization costs, far exceed gross profits. Free cash flow stands at $-88,105,872, indicating that the company is currently burning cash, which limits its immediate financial flexibility and reliance on external capital markets or internal cash reserves to fund operations. When analyzing profitability metrics, the gross margin sits at 64.5%, suggesting that the company retains a healthy portion of revenue after direct costs, yet this is insufficient to cover overheads. The operating margin is negative at -42.9%, and the profit margin is similarly depressed at -42.4%, indicating that the business model is currently unsustainable without significant cost reductions or revenue expansion. On the balance sheet, the company holds $1.20B in cash against $1.71B in debt, creating a net debt position, and the debt-to-equity ratio is listed as N/A due to the negative equity position. Despite the leverage, the current ratio of 4.84 indicates a robust short-term liquidity position, suggesting the company has ample current assets to cover its short-term liabilities. Return on Equity is N/A given the negative shareholders' equity, and the return on assets stands at -15.6%, revealing that management is currently utilizing the asset base to generate negative returns rather than positive earnings.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is reported at -143.64, a metric that implies the market is pricing in significant future earnings recovery or is currently discounting the stock heavily based on negative current performance. The price-to-book ratio is -117.21, which indicates a market valuation that is negative relative to book value, reflecting the intangible nature of the business and the current accounting losses rather than a traditional market premium over tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 11.90 and the EV/EBITDA of -30.75 suggest that investors are valuing the company primarily on its revenue growth potential and intellectual property rather than current profitability. The stock has traded between a 52-week high of $120.74 and a 52-week low of $36.36, and without the specific current price, the valuation is assessed against this wide trading range which highlights the stock's high volatility. The beta value of 1.69 indicates that the stock price is significantly more volatile than the broader market, moving with greater amplitude in response to sector-specific news or general market shifts.
Growth & Income
Revenue growth stands at 39.4% year-over-year, demonstrating strong top-line expansion, whereas earnings growth is N/A because the company remains unprofitable, implying that revenue increases are currently being consumed by operational costs rather than translating into bottom-line gains. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available capital and generated cash flow back into the business to fund its research and development activities rather than returning cash to shareholders. This growth-at-all-costs strategy is typical for biotechnology firms in the early stages of commercialization where profitability is expected to arrive later in the product lifecycle. The overall growth and income profile is characterized by rapid revenue acceleration with no current income generation, relying entirely on market confidence in future profitability to sustain the current valuation.